When Oscar Murphy received his cancer diagnosis in March 2025, the prognosis was bleak. B-cell acute lymphoblastic leukaemia — one of the most aggressive blood cancers in adults — typically gives patients six to eight months.
But on 2 January this year, the 28-year-old car salesman from Bury became the first person on the NHS to receive a revolutionary new treatment that could change everything. As a tiny bag containing 100 million genetically reprogrammed immune cells was infused into his bloodstream at Manchester Royal Infirmary, Murphy found himself marvelling at the science.
"It's very sci-fi," he told the BBC, "but if it means it gets rid of the cancer permanently and my own cells can do it, it's just fantastic."
The treatment is called obe-cel — trade name Aucatzyl — and it belongs to a class of therapies known as CAR-T. It works by taking a patient's own T-cells (white blood cells that normally fight infection), sending them to a laboratory where they are genetically reprogrammed using a harmless virus, and returning them to the body as a personalised cancer-hunting army. The modified cells recognise a protein on the surface of cancer cells, latch on like a lock and key, and mark them for destruction. Because the cells are living, they stay in the body, continuing to multiply and fight long after the infusion is complete.
The results from clinical trials have been striking. Of patients treated with obe-cel, 77 per cent went into remission. Half showed no detectable signs of cancer after an average of three and a half years. On average, the therapy gave patients 15.6 additional months of life — a transformative leap for a disease where existing treatments offer so little time.
A treatment born in Britain
Obe-cel was developed by Autolus Therapeutics, a spin-out from University College London, and is manufactured in Stevenage. NICE approved it for NHS use in England in November 2025 for adults aged 26 and over with relapsed or refractory B-cell ALL, and NHS England began funding treatment in January.
Chris Williams, 29, from Belfast, received the therapy during its experimental phase after his leukaemia returned following earlier treatment. He has now been in remission for nearly three years. "A few years ago I was very unwell and now I'm able to live a full life," he told the BBC. "I was able to go back to work. I also met Chloe and now we're engaged."
The treatment costs £372,000 per infusion at list price, though NHS England has negotiated a confidential discount. Around 50 patients a year in England are expected to benefit, with patients from Wales and Northern Ireland travelling to English centres for treatment.
Scotland is still waiting
For patients in Scotland, however, the picture is different. Obe-cel has not yet been approved north of the border.
Scotland has its own medicines approval body, the Scottish Medicines Consortium, which conducts a separate assessment from NICE. The SMC's records show that Autolus has submitted obe-cel for a full review — reference SMC2917 — but no meeting date has yet been published. Until the SMC issues its recommendation, Scottish patients with relapsed B-cell ALL cannot access the treatment on NHS Scotland.
The irony is that Scotland already has the infrastructure. The Queen Elizabeth University Hospital in Glasgow has served as Scotland's CAR-T treatment centre for years, and Aberdeen Royal Infirmary was designated as a second centre in October 2025. The expertise is there. What's missing is the green light.
Dr Rubina Ahmed, Director of Research, Policy and Services at Blood Cancer UK, has called for urgency: "It's vital that people across the UK can access it, including seeing this treatment approved in Scotland as quickly as possible."
Leukaemia UK, which played a pivotal role in the NICE approval process, said it is now actively seeking Scottish residents who have received CAR-T therapy to serve as patient representatives in future SMC discussions. "Our focus now shifts to how this new therapy will be implemented across the country, as well as what comes next for the rest of the UK," the charity said.
What Scotland's families need to hear
For the small number of Scottish adults diagnosed each year with relapsed or refractory B-cell ALL — perhaps five to ten people, based on population proportions — the stakes could not be higher. These are patients who have already endured chemotherapy, often a stem cell transplant, and have watched their cancer return. For them, obe-cel represents not just another treatment option, but potentially years of life that would otherwise be measured in months.
Oscar Murphy, who married his fiancée Lauren at Manchester Royal Infirmary in December, put it simply: "I want children and the white picket fence with my amazing wife. I just want that normality. This is my gateway to doing it."
Scotland's families deserve the same gateway. The science is proven, the infrastructure is ready, and the drug company has knocked on the SMC's door. Now it's Scotland's turn to answer.
